ArticleInternational journal of clinical and experimental pathology2015
Overexpression of PAK-1 is an independent predictor of disease recurrence in colorectal carcinoma.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Metastasis-associated DNA methylation alterations persist after accounting for immune and stromal cell heterogeneity in primary colorectal tumors.Research square · 2026Article
- Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments.Frontiers in immunology · 2025Review
- Dimethyladenosine Transferase 1 Homolog Promotes Human Gastric Carcinoma Cell Proliferation and Inhibits Apoptosis via the AKT Pathway.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Article
- The role of cell division control protein 42 in tumor and non-tumor diseases: A systematic review.Journal of Cancer · 2022Review
- PAK1 as a Potential Therapeutic Target in Male Smokers with EGFR-Mutant Non-Small Cell Lung Cancer.Molecules (Basel, Switzerland) · 2020Article
- Sterically stabilized liposomes targeting P21 (RAC1) activated kinase-1 and secreted phospholipase AOncology letters · 2020Article
- Review
- Effect of PAK1 gene silencing on proliferation and apoptosis in hepatocellular carcinoma cell lines MHCC97-H and HepG2 and cells in xenograft tumor.Gene therapy · 2018Article
- Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates.Molecules (Basel, Switzerland) · 2018Review
- FOXQ1 promotes cancer metastasis by PI3K/AKT signaling regulation in colorectal carcinoma.American journal of translational research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal carcinoma (CRC) is a significant cause of major morbidity and mortality. PAK-1 is a protein that regulates cytoskeletal dynamics and cell motility. The purpose of the present study is to investigate the relationship between PAK-1 immunoexpression and CRC progression and its validity as an independent prognostic factor. PATIENTS AND
methodsParaffin blocks of 103 primary CRCs and 37 nodal metastases were retrieved and tissue microarrays were constructed. Immunohistochemistry was performed using anti-PAK-1 antibody. Immunostaining was scored and results were analysed in relation to clinicopathological parameters.
resultsPAK-1 was overexpressed in primary CRC (P<0.001). No difference between low and high expression in nodal metastasis (P=0.139). There was no difference between PAK-1 immunoexpression in primary and nodal metastasis (P=0.275). High PAK-1 immunoexpression was associated with disease recurrence (P=0.03). However, there was no association with most clinicopathological parameters. PAK-1 overexpression was detected as an independent predictor of disease recurrence (P=0.05). No association was found between PAK-1 immunoexpression and disease free survival (log-rank =1.287, P=0.257).
conclusionPAK-1 overexpression may be involved in CRC progression and could be considered an independent predictor of disease recurrence. Further in vivo and in vitro molecular studies are needed to investigate the role of PAK-1 in colorectal carcinogenesis.
Indexed as
Identifiers
26884861PMC4730074W2438496180What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.